EXAGEN INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
EXAGEN INC. (XGN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -2.50% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2025-03-11
- EXAGEN INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -2.50%.
- EXAGEN INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -1.40%.
- EXAGEN INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -0.90%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2024-12-31 | -2.50% 10-K · filed 2025-03-11 |
| 2023-12-31 | -1.40% 10-K · filed 2025-03-11 |
| 2022-12-31 | -0.90% 10-K · filed 2024-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |